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Objective: This prospective, observational study evaluated the safety and efficacy of cryopreserved arterial allograft
reconstruction in the management of major peripheral arterial graft infections.
Methods: From April 1996 to May 2003, data from patients with major peripheral arterial graft infection who underwent
graft excision and cryopreserved arterial allograft reconstruction were prospectively collected. Arterial allografts were
harvested from multiple organ donors and cryopreserved at 80 °C. The patients were observed for survival, limb
salvage, persistence or recurrence of infection, and allograft patency. The results were calculated with the Kaplan-Meier
method.
Results: During the 7-year study period, 17 patients (14 men, 3 women; mean age, 68 years) with major peripheral graft
infection underwent graft excision and cryopreserved arterial allograft reconstruction. Eight patients (47%) had systemic
sepsis, 5 (29%) had acute ischemia at the time of the allograft reconstruction, and 9 (53%) had experienced anastomotic
rupture. Allograft reconstruction was performed as an emergency procedure in 7 patients (41%). There were no
perioperative deaths or early amputations. Two patients had allograft ruptures in the groin during the early postoperative
period. The mean follow-up period was 34 months (range, 8 to 80 months). There was no persistent or recurrent
infection, and none of the patients received long-term (>3 months) antibiotic therapy. Reoperation for allograft revision,
excision, or replacement was performed in 2 patients. The 18-month primary and secondary allograft patency rates were
68% and 86%; the overall limb salvage rate was 82% at 2 years.
Conclusion: Our experience with cryopreserved arterial allograft in the management of major peripheral bypass graft
infection suggests that this technique seems to be a useful option for treating one of the most dreaded vascular
complications. ( J Vasc Surg 2005;41:30-7.)Major peripheral arterial graft infection is an uncom-
mon but severe and potentially devastating complication of
vascular surgery that is associated with significant mortality
and high amputation rates.1-3 The basic goal of therapy in
patients with lower-extremity graft infection is to eradicate
infection andmaintain adequate perfusion. Radical excision
of infected perigraft tissue is the recommended treatment
to eradicate infection and is mandatory in cases of systemic
sepsis, anastomotic disruption, or graft occlusion.4,5 Autol-
ogous saphenous veins are considered the best arterial
substitute for lower-extremity revascularization in infected
fields, but they are often unavailable or unsuitable in these
patients.6
Having been faced with this dilemma and encouraged
by good long-term results obtained with cryopreserved
arterial allograft reconstructions in infected prosthetic
grafts and mycotic aneurysms of the abdominal aorta,7,8 we
investigated cryopreserved arterial allografts in the manage-
ment of major peripheral arterial graft infection. This pro-
spective observational study evaluated the safety and effi-
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30cacy of cryopreserved arterial allograft reconstruction in the
latter indication. The main variables studied were patient
survival, freedom from persistent or recurrent infection,
allograft patency, and avoidance of major amputation.
PATIENTS AND METHODS
From April 1996 to May 2003, data from patients with
major peripheral bypass graft infection treated by graft
excision and cryopreserved arterial allograft reconstruction
in the Department of Vascular and Thoracic Surgery at our
institution were prospectively collected. These data in-
cluded demographics, atherosclerotic risk factors, original
procedures, modes of presentation, surgical details, periop-
erative morbidity, and bacteriologic findings.
The diagnosis of peripheral bypass graft infection was
made by using clinical criteria, ultrasound scanning, com-
puted tomographic scanning, and bacteriology tests. Indi-
cations for graft excision were systemic sepsis, disrupted
anastomosis (infected pseudoaneurysm or hemorrhage),
graft occlusion, infection due to virulent gram-negative
organisms, infection of the entire graft, or a combination of
these criteria.
The decision to perform revascularization in patients
whose limbs were salvageable and whose vessels could be
reconstructed was made on indication for initial peripheral
bypass grafting, clinical presentation at the time of allograft
reconstruction, and arteriographic findings. A cryopre-
served arterial allograft was used after first considering
revascularization with autologous greater saphenous veins
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nous veins were not considered). The patients initially
underwent treatment with broad-spectrum intravenous an-
tibiotics.
Surgical technique. Bacteriology culture tests were
performed on the perigraft fluid and the infected graft.
Wounds were carefully excised to obtain macroscopically
normal tissue. To make sure that all involved infected tissue
was completely resected, the anastomotic and perianasto-
motic regions were dissected and exposed thoroughly dur-
ing surgery.
Dissection of popliteal and tibial arteries was restricted
to the presenting aspect only, with no circumferential dis-
section and without the use of arterial clamps (Esmarch
bandage). The arterial allografts were implanted using
polypropylene sutures for proximal and distal anastomoses.
The allograft was tunneled using the previous pathway (in
situ) or a new pathway, depending on the location of the
sepsis. To allow close surveillance, the arterial allograft was
routed subcutaneously when possible.
Once reconstruction had been completed, arteriogra-
phy was routinely performed when the allograft extended
into an infrageniculate outflow site, any technical errors or
problems were corrected immediately, and another radio-
graph was taken to confirm a satisfactory situation. All
incisions were drained, and the skin was closed primarily in
all cases. Fasciotomy was routinely performed in patients
who presented with acute limb ischemia.
Arterial allograft. Harvesting, preservation, and
preparation of allografts have been previously described.8,9
Arterial allografts (aortic bifurcation, iliac, femoral, and
popliteal arteries) were carefully harvested from brain-dead
multiple-organ donors. Informed consent was given by the
donor’s family, in accordance with French law. Bacteriol-
ogy and virology tests were performed for all donors.
After harvesting, arterial allografts were flushed with
heparinized saline solution to eliminate any residual intra-
arterial blood and stored at 4 °C in M199 medium (Gibco
Laboratories, Gaithersburg, Md) containing gentamicin
(0.50 mg/mL) and amphotericin B (0.25 mg/mL). The
delay before freezing did not exceed 18 hours in all cases.
Allografts were permeated for 20 minutes at 4 °C in M199
medium containing 12% dimethylsulfoxide and subse-
quently frozen at80 °C without rate-controlled freezing.
Allografts were stored an average of 48  21.4 days.
Upon request from the vascular surgeon, the bag con-
taining the artery was rapidly thawed by immersion in water
prewarmed to 37 °C. Once the ice had melted, allografts
underwent successive washouts in heparinized saline solu-
tion at room temperature. The final washout fluid was
sampled for bacteriology culture.
Because of the few available allografts, matching blood
compatibility between recipient and donor was not possible
in all cases. Cryopreserved arterial allografts were ABO
compatible with the recipient in 14 patients (82%) and
mismatched in 3 patients. None of the patients received
immunosuppression therapy.Postoperative management and follow-up examination.
Intravenous antibiotics were administered for 2 weeks, and
culture-determined oral antibiotics were continued for 6
weeks. After discharge, routine late follow-up included a
clinical and duplex scanning examination at 1 month and
every 6 months thereafter. Late arteriography was per-
formed depending on the results of duplex scanning. Pa-
tients were routinely prescribed daily low-dose aspirin (100
mg). For the purposes of this report, the status of all
survivors was updated in April 2004. Patency, limb salvage
rate, and survival were determined with the Kaplan-Meier
method.
RESULTS
Patients and initial procedures. During the 7-year
study period, 17 patients (14 men, 3 women; mean age of
68 years, range, 50 to 83 years) who had major peripheral
graft infection underwent graft excision and cryopreserved
arterial allograft reconstruction. The baseline characteris-
tics of the patients are shown in Table I. Systemic risk
factors for infection, including diabetes mellitus, malig-
nancy, steroid use, and malnutrition were present in 7
patients (41%).
The indications for initial peripheral bypass grafting
were critical leg ischemia in 10 (59%) patients, severe
claudication in 5 (29%), and popliteal aneurysm in 2 (12%).
The types and indications of initial peripheral reconstruc-
tions with infection are described in Table II. Prosthetic
femoropopliteal bypass was the most frequently infected
reconstruction. Graft material was polytetrafluoroethylene
(PTFE) in 10 patients, Dacron in 3, and autologous saphe-
nous vein in 4.
The median time from placement of the bypass to the
Table I. Clinical characteristics of the 17 patients with
peripheral graft infection
Clinical characteristics Value (%)
Age (y)
Mean  SD 68  8.75
Range 50-83
Sex
Male 14 (82)
Female 3 (18)
Cigarette smoking 14 (82)
Hypertension 12 (70)
Dyslipidemia 5 (29)
Coronary artery disease* 9 (53)
Cerebrovascular event† 2 (12)
Obesity 3 (18)
Diabetes mellitus 4 (23)
Malignancy 1 (6)
Steroid use 1 (6)
Malnutrition‡ 3 (18)
*Six patients had coronary artery bypass.
†Cerebrovascular event was defined as a transient ischemic attack or stroke or
prior carotid endarterectomy.
‡Malnutrition was defined as recent weight loss of greater than 15% body
weight, a body weight below ideal body weight by at least 15%, or both.initial symptom of graft infection was 22 days (range, 10
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(65%) of the 17 patients. The median time from graft
placement to definitive treatment of the graft infection was
31 days (range, 10 days to 72 months). Six (35%) of these
17 patients had been initially operated on in our center,
whereas 11 (65%) were referred to us after a mean of 2.1
1.3 operations (range, 1 to 5) had been performed else-
where.
Manifestation and preoperative diagnosis. The clin-
ical events in 17 patients with an infected peripheral graft
are described in Table III. One false aneurysm developed at
the below-knee popliteal level and resulted in a neurologic
deficit due to tibial nerve compression. Because of arterial
status, failed reoperations, or end-to-end bypasses, restora-
tion of lower-limb arterial circulation was required to sal-
vage the limb after removal of the infected patent graft in
the 12 patients without acute ischemia.
Graft infection was localized to the area of the proximal
anastomosis in 4 patients (23%), to the area of the distal
anastomosis in 4 (23%), and involved the entire graft in 7
(41%). Two patients (12%) had isolated areas of infections
involving a portion of a prosthetic graft distant from both
anastomotic sites. According to the classification of graft
infection from the Montefiore Medical Center,2 all the
patients in this series had major graft infections at the time
of presentation:
● 2 patients with group III (infections involved the body of
the graft but not an anastomosis);
● 2 patients with group IV (infections surrounded an
exposed anastomosis but bacteremia or anastomotic
Table II. Types and indications of peripheral
reconstructions with infection in 17 patients
Reconstruction Material n Indication
Axillobifemoral Dacron 1 CLI
Crossover
femorofemoral
PTFE 1 Claud
Iliofemoral PTFE 1 Claud
Iliofemoral patch
angioplasty
Dacron 1 Claud
Iliofemoral patch
angioplasty 
femoropopliteal
(AKPA)
Dacron 1 CLI
Iliopopliteal (AKPA) PTFE 1 CLI
Femoropopliteal
(AKPA)
PTFE 2 Claud
Femoropopliteal
(BKPA)
PTFE 4 CLI (2)/Fempop
GSV 1 Aneur (2)
CLI
Femorotibial* PTFE 1 CLI
GSV 3 CLI
BKPA, Below-knee popliteal artery; AKPA, above-knee popliteal artery;
PTFE, polytetrafluoroethylene; GSV, greater saphenous vein; Ilio, external
iliac artery; CLI, critical limb ischemia; Claud, claudication; Fempop aneur,
femoropopliteal aneurysm.
*Site of proximal anastomosis was an aortofemoral graft in 1 patient.bleeding had not occurred); and● 13 patients with group V (infections involved a graft-to-
artery anastomosis and were associated with septicemia,
anastomotic bleeding, or both).
Because of acute bleeding in 2, a severe neurologic deficit in
1, and severe acute ischemia in 4, allograft reconstruction
was performed as an emergency procedure in 7 patients
(41%), whereas it was a planned procedure in 10 patients
(59%).
Treatment. Bacteriology cultures were positive in all
cases and are listed in Table IV. A single organism was
identified in 10 (59%) cultures and multiple organisms in 7
(41%). Infection was due to a variety of organisms, most
frequently Staphylococcus aureus followed by Pseudomonas
aeruginosa.
In 14 patients (82%), the greater saphenous veins were
not available either because they had already been used in
other revascularizations or had been stripped. In 2 patients,
the saphenous vein was present but was deliberately not
used because of a discrepancy between the diameter of the
vein and the external iliac artery. A unique greater saphe-
nous vein was used in 1 patient for a femorofemoral cross-
over in addition to allograft reconstruction. During the
study period, 7 patients were treated with greater saphe-
nous vein reconstruction for peripheral graft infection (3
crossover, 1 iliofemoral, and 3 femoropopliteal bypasses).
At surgery, removal of the entire graft was felt to be
mandatory in 100% of patients with infected prosthetic
grafts and in 50% with infected saphenous grafts. In the
latter 2 patients, the distal end of the saphenous was pre-
served as a “cuff” for a distal allograft anastomosis. Types of
arterial allograft reconstruction for all 17 patients are de-
tailed in Table V.
The proximal anastomosis was located at the same level
in 7 patients (41%) and was different in 10 (59%). The distal
anastomosis was located at the same level in 9 patients
(53%) and was more distal in 8 (47%). Reconstruction was
performed in situ in 6 patients (35%) and ex situ in 11
(65%). Of the 3 patients with iliofemoral infection, the
allograft was placed in situ in 2 cases and a crossover was
made in 1. Subcutaneous routing was performed in 13
Table III. Clinical events of the 17 patients with
infected peripheral graft
Events n (%)
Sepsis (fever, leukocytosis, blood positive culture) 8 (47)
Anastomotic rupture 9 (53)
Hemorrhage 6
Pseudoaneurysm* 3
Acute ischemia 5 (29)
grade IIa 4
grade IIb 1
Infected sinus tract 5 (29)
Abscess adjacent to the graft 2 (11)
Graft exposure 5 (29)
*Including 1 patient with tibial nerve compression and neurologic deficit.patients (76%).
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fibrinolysis of the tibial arteries during the procedure in 2,
and surgical drainage of suppurative arthritis of the knee in
1. No myoplasty was performed. The mean duration of the
procedures was 306 minutes (range, 200 to 440).
Early outcome (<3 months). There were no periop-
erative deaths, no early occlusions of the allograft recon-
struction, and no early amputation in this series. Five
patients (29%) had complications that were not related to
the allograft: transient renal failure in 2, delirium tremens in
1, neurologic postischemic sequelae of the limb in 2, and
congestive heart failure in 1.
Two patients had allograft ruptures in the groin on
postoperative days 20 and 45. The previously infected
groin in these two patients had been re-exposed and no
myoplasty had been performed during allograft reconstruc-
tion. Healing was delayed and skin necrosis occurred, re-
sulting in arterial allograft exposure and subsequent rup-
ture. Both patients underwent emergency surgery with an
uneventful recovery.
The first patient had undergone a femorofemoral and a
distal extension to peroneal artery allograft reconstruction.
Infection of the initial arterial graft was due to S. aureus,
and the patient was treated with an oral antistaphylococcus
regimen (oxacillin) at the time of rupture. After the proxi-
mal end of the distal extension ruptured, the distal exten-
sion of the allograft was reimplanted in the profunda fem-
oral artery and a myoplasty was performed.
The second patient had undergone a complex allograft
reconstruction associating an iliofemoral and a femoro-
femoral crossover plus femoropopliteal revascularization.
Infection of the initial arterial graft was due to S. aureus
associated with P. aeruginosa, and the patient was treated
with an oral antibiotics regimen (pristinamycin and cipro-
floxacin) at the time of rupture. After the proximal end of
the femorofemoral crossover ruptured, the femorofemoral
crossover was ligated and a prosthetic (PTFE) axillofemoral
was performed as an inflow conduit for the femoropopliteal
allograft. At the time of reoperation, there were no clinical
or biological signs of persistent infection and bacteriology
cultures from surgery were negative in both cases. The two
allografts that ruptured had been stored for a period of 27
and 53 days.
Blood transfusion was required in 10 patients (59%)
Table IV. Bacteriology of peripheral graft infections in 17
Single orga
No. of patients (%) 10 (59
Organisms (No.) Staphylococcus aure
Staphylococcus epidwith a mean of 4.8 red blood cell units (range, 2 to 10units) per patient. Mean duration of hospitalization was 24
 12.6 days.
Late outcome. All patients were available for follow-
up (mean, 34 months; range, 8 to 80 months). Six patients
died during late follow-up in postoperative months 8, 9,
18, 22, 30, and 52, none for treatment-related reasons.
Causes of later deaths were myocardial infarction in 4,
prostate cancer in 1, and pulmonary embolism in 1. The
cumulative survival rate was 88% at 1 year and 74% at 2
years.
Four allografts thrombosed during follow-up at 6, 7,
12, and 20months. The 3 patients whose grafts occluded at
7, 12, and 20 months did not undergo surgery because of a
very poor runoff. Two of them had occlusion of a femo-
rotibial extension with a patent femorofemoral crossover
and required below-knee amputation. The third patient
had a thrombosed femoropopliteal reconstruction that re-
sulted in critical limb ischemia. The fourth patient under-
went successful thrombectomy at 6 months (which was still
patent at 23 months).
Aneurysmal deterioration of the cryopreserved allograft
ents
Multiple organisms
7 (41)
) Staphylococcus aureus (4)
is (2) Pseudomonas aeruginosa (6)
Proteus mirabilis (1)
Bacteroides fragilis (1)
Enterobacter cloacae (1)
Enterobacter faecalis (1)
Morganella morganii (1)
Table V. Types of arterial allograft reconstructions with
infection in 17 patients
Reconstruction n
Subclavian-brachial  axillofemoral* 1
Crossover femorofemoral 1
Crossover femorofemoral  iliofemoral 
femoropopliteal (BKPA)
1
Crossover femorofemoral  femorotibial 2
Iliofemoral 1
Iliofemoral  femoropopliteal (AKPA) 1
Iliofemoral  femorotibial 2
Common iliac-popliteal (BKPA) 1
Iliotibial 1
Femoropopliteal (BKPA) 1
Femorotibial† 5
BKPA, below-knee popliteal artery; AKPA, above-knee popliteal artery;
Ilio, external iliac artery.
*A femoral allograft conduit was used to perform the axillohumeral bypass,
an ilio-femoropopliteal allograft conduit was used to perform the axil-
lofemoral, and great saphenous vein was used for the femorofemoral cross-
over.
†Site of proximal anastomosis was an aorto-femoral graft in one case.pati
nism
)
us (8
ermidoccurred twice in 1 patent, graft requiring 2 segmental
with
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died of myocardial infarction 16 months after the last
procedure with a patent allograft.
There was no persistent or recurrent infection, and
none of the patients received long-term (3 months) or
indefinite antibiotic therapy. The 18-month primary and
secondary allograft patency rates were 68% and 86% (Fig 1).
The overall limb salvage rate was 82% at 2 years (Fig 2).
DISCUSSION
Our experience with cryopreserved arterial allografts in
the management of major peripheral bypass infections sug-
gests that this technique is a useful option for treating one of
the most dreaded vascular complications. Although the num-
ber of cases reported is small, this is the largest surgical series
dealing with cryopreserved arterial allograft in the manage-
ment of peripheral bypass infection described in the literature.
Most patients in this series represent the most desperately ill
patients presenting with peripheral bypass infection. Eight
patients (47%) had systemic sepsis, 5 (29%) had acute ischemia
at the time of allograft reconstruction, and 9 (53%) had
experienced anastomotic rupture. In addition, multiple or-
ganisms were present in 41%, including virulent P. aeruginosa
in 35%. Despite these difficulties, there were no perioperative
deaths or early amputations in this series.
The optimal management of major peripheral graft
infection is still controversial. Total graft excision is gener-
ally required if any of the following conditions exist: (1)
signs of systemic sepsis, (2) anastomotic disruption, (3) the
presence of virulent gram-negative organisms on culture,
(4) involvement of the entire graft, or (5) associated graft
thrombosis. All the patients in this series presented one or
more preoperative conditions and required total graft exci-
sion. However at surgery, the distal part of the vein was
Fig 1. Primary and secondary patency ratesjudged to be uninfected in 2 patients who had an infectedsaphenous graft, and it was successfully preserved as a
“cuff” for allograft anastomosis. All the patients in this
series required arterial reconstruction to preserve limb via-
bility, whereas none had available or suitable saphenous
veins to perform a complete lower-limb arterial reconstruc-
tion.
We embarked on a cryopreserved allograft replacement
program because
● We were dissatisfied with the more conventional treat-
ments in terms of mortality, reinfection, and amputation
rates.
● Cryopreserved arterial allograft reconstruction is highly
applicable in the management of serious graft infection,
even for emergency use.8
● The results of experimental studies and clinical results
suggest that arterial allografts have a good resistance to
infection.8,10-12
● Arterial allografts harvested from brain-dead donors are
available as part of an active, local, multiorgan transplant-
retrieval program.
None of the patients in this series experienced persis-
tent or recurrent infection. Although two allograft ruptures
occurred in 2 patients in the early postoperative period, we
feel that these ruptures were due to allograft exposure
rather than to infection because no objective clinical or
biological signs of persistent or recurrent infection were
found during reoperation and bacteriology cultures from
surgery were negative.
Although another concern could be whether a longer
follow-up period will reveal recurrent infection, the mean
follow-up period of 34 months, with all allografts observed
for at least 8 months, is reassuring. Furthermore, no rein-
fections occurred in the 2 patients who required implanta-
life-table analysis. Error bars represent SEM.tion of a new prosthetic graft.
able
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replacement is safe for all types of infection. Indeed, caution
should be taken when an in situ allograft replacement is
planned in a patient with extensive infection and gross
purulence or highly virulent gram-negative organisms.
Thus, in 11 patients in this series who required complete
graft removal, allografts were routed ex situ to avoid place-
ment in an extensively contaminated bed. Moreover, care-
ful wound excision, removal of the entire prosthetic graft,
and perioperative intravenous administration of appropri-
ate antibiotics were important factors for successfully erad-
icating infection in this series.
Early rupture of the allograft is a potentially devastating
and specific complication of allografting. Fractures from
cryopreservation and thawing have been reported both
clinically and experimentally.13,14 Hunt et al15 provide
evidence that the mechanical stresses that build up between
80 °C and 196 °C during the cryopreservation process
could be responsible for fractures. Furthermore, clumsy
handling during the thawing process could trigger lesions
of the extracellular matrix that could be responsible for later
ruptures.16 Exposure of the allograft secondary to wound
breakdown had also been reported as a cause for allograft
rupture.17,18 However, especially for aortic allografts, most
early ruptures seemed to be caused by infection. Infection
with highly virulent organisms is a logical risk factor for
allograft infection and subsequent rupture. This probably
accounts, at least in part, for the significantly higher mor-
tality after allograft replacement to treat secondary aortoen-
teric fistulas.10,19-21
As 15 (88%) of 17 patients in this series had severe
underlying occlusive disease and 5 were referred with acute
Fig 2. Limb salvage rate with life-tischemia, they were obviously at high risk of limb loss.Therefore, it is important to note that that the 18-month
primary and secondary allograft patency rates were 68% and
86%, and there were no early amputations and only two late
below-knee amputations in our patients. This low amputa-
tion rate was consistent with the treatment of policy of
immediate revascularization. After a mean follow-up period
of 34 months, 5 allografts failed (4 from thrombosis, 1
from aneurysmal dilatation) which resulted in 3 successful,
technically uncomplicated interventions.
Despite this relatively good success rate, arterial allo-
graft reconstruction in major peripheral graft infection has
some obvious disadvantages:
● Wound healing could not be obtained in 2 patients, and
bleeding occurred in 2 because of allograft exposure. As
a result, coverage by muscle transposition should be
performed in infected groin anastomoses even when
allograft reconstruction is performed.
● Allograft failure from thrombosis and aneurysmal dete-
rioration was not uncommon in this series, confirming
that these allografts must be closely monitored and that
subcutaneous tunneling of the grafts is an important part
of the surgical technique.
● With longer follow-up, the incidence of secondary and
late aneurysmal deterioration is expected to increase.
● With longer follow-up, the incidence of allograft throm-
bosis is expected to increase as well. Albertini et al22
reported a poor long-term patency rate of 42% at 3 years
in a group of 148 patients who experienced arterial
allograft below-knee bypasses for limb salvage.
In this series, arterial allograft was used after revascu-
larization with autologous greater saphenous veins was first
analysis. Error bars represent SEM.considered. Arm and femoropopliteal veins were not con-
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very relevant option for revascularization in infected fields.
Very good revascularization results have been obtained
with femoropopliteal or arm veins for aortic or peripheral
infection and critical limb ischemia.23-26
Harvesting and preparing these two types of conduits
are technically demanding (with the need to perform an-
gioscopy in the case of an arm vein) and time-consuming
procedures. Furthermore, harvesting the femoropopliteal
vein in the absence of the greater saphenous vein may lead
to venous sequelae. Reconstruction with femoropopliteal
or arm veins often necessitates a specialized two-team ap-
proach to expedite the operation and to splice the compos-
ite vein using venovenostomy to create a vein conduit of
sufficient length to allow the performance of the lower-
extremity revascularization. Finally, in our opinion, this
approach may be difficult in sick and infected patients who
need urgent treatment.
Few series reported vascular allograft reconstruction
after excision of an infected peripheral bypass graft. After in
situ fresh venous allograft reconstruction in 5 patients with
patent peripheral prosthetic graft infection, Snyder et al27
reported complete resolution of infection in all cases. More
recently, Fujitani et al6 reported the use of cryopreserved
homograft veins to eradicate infection and achieve limb
salvage in all 6 patients with infected peripheral prosthetic
grafts with a limited follow-up of 9.5 months.
Patency rates reported by many investigators with cryo-
preserved venous allografts for limb salvage were low, how-
Table VI. Documented cases of management of peripher
reported in the literature.*
Reference N
Location of infected
graft Material
Partia
or tota
graft
remova
Bracale et al32
(1999)
2 Axillofemoral PTFE
Dacron
Total/2
Locati et al133
(2000)
2 Axillobifemoral PTFE Partial/
Desgranges et
al34 (1998)
5 2 Femoropopliteal
1 Femorofemoral
2 Iliofemoral
SV
Prosthetic
Prosthetic
Partial/
Total/1
Total/2
Wagstaff et al17
(1996)
4 1 Iliofemoral
1 Femorotibial
1 Femoropopliteal
1 Crossover
Dacron
AV
PTFE
Dacron
At least
total
graft
remov
Nevelsteen et
al21 (1998)
3 3 Femorodistal Prosthetic Total
Lavigne et al16
(2003)
4 3 Femoropopliteal
1 Femorofemoral
Prosthetic Total
Locati et al35
(2000)
1 Femorotibial PTFE Total
SV, Saphenous vein; PTFE, polytetrafluoroethylene; AV, arm vein.
*Axillobifemoral or bilateral axillofemoral following removal infected aortic
†Mean follow-up of the indicated series that included patients treated for p
the dagger.ever28,29 The largest experience was reported by Farber etal,30 who performed 240 infrainguinal revascularizations
for limb salvage and achieved a primary patency rate of 30%
at 1 year and 18% at 2 years. Our experience was very
similar, causing us to abandon this conduit for distal revas-
cularization.9,31
We found 21 documented cases of arterial allograft
reconstruction after excision of an infected peripheral by-
pass graft reported in the English literature.16,17,21,32-35
The location of the infected grafts and the outcome of these
21 cases are presented in Table VI. Reported results were
good, with no reinfection, one perioperative death, and
one early amputation, but it is difficult to draw any conclu-
sion from a group of small series or case reports.
The heterogeneity of patients, the numerous therapeu-
tic strategies, and the general diagnosis of peripheral graft
infection make comparisons between series very difficult.
Nevertheless, we think that the outcome of the midterm
follow-up in our series for mortality, limb salvage, and
freedom from reinfection compare favorably to other series
using more conventional methods.1-3,36 To compare dif-
ferent series of peripheral bypass infections, a system is
needed to stratify these patients using standards similar to
those that have been developed in other areas of vascular
surgery.37,38
Conclusion. Although this study presents a small se-
ries of patients with limited follow-up, reconstruction with
a cryopreserved arterial allograft seemed to be a useful
option for treating one of the most dreaded vascular com-
plications. When major peripheral graft infection occurs in
pass infection with cryopreserved arterial allograft
erioperative
mortality
Early
amputation
Late
amputation
Secondary
infection
Mean
follow-up
(months)
0 0 0 0 13.5
0 0 0 0 21
/5 (20%) 1 0 0 20 (18†)
0 0 2 0 24.5 (7†)
0 0 0 0 24.5 (30†)
0 0 1 0 18 (22†)
0 0 0 0 18
hetic graft were excluded.
tic aortic graft infection, number of patients in each series is indicated afteral by
l
l
l
P
2
2 1
3
al
prost
rosthepatients with severe underlying occlusive disease and autol-
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Volume 41, Number 1 Castier et al 37ogous conduits are unavailable or unsuitable, the high
operativemortality, reinfection, and amputation rates are of
major concern and may be reduced with the use of these
allografts.
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